Spectrum Pharma: (NASD: SPPI)
$8.14
0.06 (0.74%)
Volume 711,020
May 17 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 8.03 - 8.18 |
| 52wk Low - High | 6.92 - 17.48 |
| Previous Close | 8.08 |
| Avg. Volume | 949,331 |
| Industry | MED-DRUGS |
| Market Cap | 489.68 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.40 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.08 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
88 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.08 |
| Current Quarter Estimate | -0.03 |
| Most Accurate Estimate | -0.03 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-07-2013 |
| EPS Last Year | 0.85 |
| Expected Earnings Growth | NA |
Company Description
Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.03 | -0.02 | -0.08 | 0.16 |
| Number of Estimates | 1 | 1 | 1 | 1 |
| Low Estimate | -0.03 | -0.02 | -0.08 | 0.16 |
| High Estimate | -0.03 | -0.02 | -0.08 | NA |
| Year Ago EPS | 0.34 | 0.39 | 1.19 | -0.08 |
| EPS Growth | -108.82% | -105.13% | -106.72% | 300.00% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| SPECTRUM PHARMA | SPPI | 8.14 | |
|
| JAZZ PHARMACEUT | JAZZ | 58.36 | |
|
| SALIX PHARM-LTD | SLXP | 59.28 | |
|
| SANTARUS INC | SNTS | 21.91 | |
|
| USANA HLTH SCI | USNA | 65.46 | |
|
| BIOCRYST PHARMA | BCRX | 1.71 | |
|
| CATALYST PHARMA | CPRX | 0.83 | |
|
| CELL THERAPEUT | CTIC | 1.16 | |
|
| CUBIST PHARM | CBST | 49.51 | |
|
| ELAN CP PLC ADR | ELN | 11.67 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Spectrum Pharma Reports 1Q Loss
May 14, 2013
Spectrum Progresses with SPI-2012
Apr 09, 2013
SPPI Acquires Late-Stage Candidate
Mar 18, 2013
Spectrum Guides Lower 2013 Revenue
Mar 13, 2013
SPPI Beats in 4Q on Higher Sales
Feb 25, 2013
Spectrum Acquires Apaziquone Rights
Feb 04, 2013
Positive Data on Spectrum Candidate
Jan 29, 2013
Patent Extension at Spectrum Pharma
Jan 22, 2013
Financials
| EPS TTM | 0.85 |
| Sales | 268 |
| Net Income | 45 |
| Price/Earnings | 9.58 |
| Price/Book | 1.72 |
| Price/Cash Flow | 6.47 |
| Price/Sales | 1.99 |
News
Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma - TheStreet.com
May 17, 2013
How Dangerous are Five of the Most Heavily Shorted Small Cap Stocks? - Benzinga
May 17, 2013
The 5 Dumbest Things on Wall Street This Week: May 17 - TheStreet.com
May 17, 2013
Maxygen Ranks the Lowest in Terms of P/E Ratio in the Biotechnology Industry (MAXY, SPPI, PDLI) - Financial News Network Online - News Corner
May 15, 2013
Spectrum Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference - Close-Up Media
May 15, 2013
Spectrum Pharmaceuticals to Take Part in UBS Global Healthcare Conference - Close-Up Media
May 15, 2013
Spectrum Pharmaceuticals Shares Climbing Higher, Up 2.9% - Financial News Network Online - Market Movers
May 14, 2013
Law Offices of Todd M. Garber Announces Investigation of Spectrum Pharmaceuticals, Inc. - Globenewswire
May 13, 2013
Broker Recommendations
| Current ABR | 1.50 |
| ABR (Last Week) | 1.50 |
| # of recs in ABR | 2 |
| Average Target Price | 16.50 |
| Industry Rank by ABR | 88 out of 265 |
| Rank in Industry | 17 out of 91 |
